Johnson & Johnson (NYSE:JNJ) Downgraded to Hold Rating by Wall Street Zen

Wall Street Zen lowered shares of Johnson & Johnson (NYSE:JNJ) from a buy rating to a hold rating in a research report report published on Saturday morning.

JNJ has been the topic of several other research reports. Loop Capital set a $190.00 target price on shares of Johnson & Johnson in a research note on Wednesday, October 22nd. Bank of America upped their price objective on Johnson & Johnson from $204.00 to $220.00 and gave the company a “neutral” rating in a research report on Monday, December 15th. Wells Fargo & Company lifted their target price on Johnson & Johnson from $212.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, December 12th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Johnson & Johnson in a report on Friday, October 31st. Finally, The Goldman Sachs Group increased their price objective on Johnson & Johnson from $213.00 to $240.00 and gave the company a “buy” rating in a research report on Thursday, December 18th. Four research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and an average target price of $213.33.

Johnson & Johnson Price Performance

JNJ opened at $218.81 on Friday. The firm has a market cap of $527.18 billion, a PE ratio of 21.12, a P/E/G ratio of 2.25 and a beta of 0.34. The stock has a 50-day moving average price of $205.82 and a 200-day moving average price of $186.95. Johnson & Johnson has a 1 year low of $141.50 and a 1 year high of $220.11. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be given a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.4%. The ex-dividend date of this dividend is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 50.19%.

Hedge Funds Weigh In On Johnson & Johnson

Institutional investors have recently made changes to their positions in the business. Abich Financial Wealth Management LLC bought a new stake in shares of Johnson & Johnson during the 3rd quarter valued at $26,000. Evolution Wealth Management Inc. bought a new stake in Johnson & Johnson during the second quarter valued at about $27,000. Clayton Financial Group LLC purchased a new stake in Johnson & Johnson in the third quarter worth about $28,000. Semmax Financial Advisors Inc. raised its stake in shares of Johnson & Johnson by 55.0% in the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock worth $31,000 after buying an additional 72 shares during the period. Finally, GFG Capital LLC purchased a new position in shares of Johnson & Johnson during the 2nd quarter valued at about $35,000. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.